SEP2026
A recent US national study has found broad public support for access to IVF and for insurance coverage of fertility treatment. According to the study, 74.2% of US adults support the right of patients experiencing infertility to pursue IVF, while 64.6% support state laws requiring insurers to cover fertility treatments such as IUI and IVF. The survey also found that approximately 8.9% of respondents reported having experienced infertility.
For fertility clinics, clinic groups, investors, employers, insurers and industry partners, this is an important market signal. While US fertility law and insurance coverage remain highly fragmented from state to state, public opinion appears to show clear support for IVF as a legitimate and necessary part of reproductive healthcare.
IVF in the US is widely supported but access remains uneven
The findings are particularly relevant because the US does not have one uniform national fertility-access framework. IVF access, insurance coverage, embryo-related laws, surrogacy rules and provider protections vary significantly across states. This means that public support for IVF does not automatically translate into equal access. Many patients in the US still face high out-of-pocket costs, limited insurance coverage, state-specific legal uncertainty and unequal access depending on employer benefits, location, plan design and income.
For fertility providers, this creates both a challenge and an opportunity. Clinics must navigate a complex legal and reimbursement landscape, while also responding to growing expectations that fertility treatment should be more accessible, better financial coverage and more transparently explained.
Why insurance coverage matters commercially
Insurance coverage can have a direct impact on demand, patient conversion and treatment continuation. Where patients have coverage, they may be more likely to proceed from consultation to treatment, continue after a failed cycle, or pursue the treatment pathway most appropriate for their medical situation. Where coverage is limited, fertility care often remains dependent on self-pay ability. This can reduce access, delay treatment, create affordability concerns and increase dropout before or during treatment.
For fertility clinics coverage expansion may influence:
- patient acquisition and conversion,
- treatment volume,
- cycle continuation rates,
- demand for IVF, IUI and fertility preservation,
- use of donor sperm, donor eggs and donor embryos,
- employer-benefit partnerships,
- payer contracting strategy,
- clinic footprint and market-entry decisions.
Why this matters for fertility clinics and clinic groups
The survey supports a broader trend as fertility treatment is increasingly being viewed as part of mainstream healthcare rather than an optional or niche service. For fertility clinics and groups, this reinforces the importance of understanding local market conditions, including:
- state-level fertility insurance mandates,
- employer benefit penetration,
- patient affordability,
- payer mix,
- local competition,
- state-specific legal protections or uncertainties,
- demand for donor conception and fertility preservation,
- patient communication around costs and coverage.
In the US, two clinics operating in different states may face very different market conditions even if their clinical offering is similar. This makes state-by-state analysis increasingly important for expansion, acquisition, investor due diligence and commercial planning.
Why this matters for employers and benefit providers
The finding that nearly two-thirds of respondents support state laws requiring fertility coverage is also relevant for employers and fertility-benefit providers. Employer-sponsored fertility benefits have become an important access route in the US. For companies competing for talent, fertility and family-building benefits may be part of a broader employee wellbeing, diversity and retention strategy.
However, benefit design matters. A fertility benefit that covers only a narrow set of services may still leave patients with substantial out-of-pocket costs. Coverage may differ for IVF, IUI, fertility preservation, donor gametes, surrogacy-related care, medication, storage, genetic testing and counselling.
For employers and benefit platforms, the challenge is to design programmes that are understandable, equitable and clinically meaningful.
We have earlier participated in a whitepaper discussing such topics in more depth together with Kindbody: https://www.kindbody.com/fertility-without-borders/
Why this matters for investors and industry partners
For investors, the study provides useful demand-side context. Public support for IVF access and insurance coverage suggests that fertility services are likely to remain politically and commercially important. However, the US fertility market cannot be assessed as one uniform market. State-level differences in law, coverage, employer-benefit penetration, provider concentration and patient affordability remain central to market attractiveness.
For suppliers, technology companies and service providers, this means commercial strategy should consider not only clinic numbers and cycle volumes, but also:
- insurance coverage dynamics,
- state-specific ART protections,
- payer and employer benefit trends,
- clinic network consolidation,
- patient affordability,
- donor and third-party reproduction regulation,
- demand for tools improving efficiency, conversion and patient experience.
Public support does not remove legal uncertainty
The study also comes at a time when US ART law remains politically and legally active. Some states have moved to strengthen IVF protections, while others have introduced or considered embryo-status, reporting or oversight measures that could affect fertility care.
This means that public support for IVF access and insurance coverage is encouraging, but it does not remove the need for careful legal, regulatory and market monitoring. For fertility organisations, the key message is that the US fertility landscape must still be assessed state by state.
Strategic takeaway
The new US public-opinion data shows strong support for IVF access and fertility insurance coverage. But support does not equal access.
Until fertility coverage and ART protections become more consistent, the US fertility market will remain shaped by a complex combination of state law, employer benefits, insurance design, patient affordability and clinic-level strategy. For fertility clinics, investors and industry partners, this reinforces the need for structured market intelligence, state-by-state assessment and clear patient-facing communication around access, cost and coverage.
At Fertility Consultancy, we follow these developments closely because the future of fertility care depends not only on clinical excellence, but also on access, regulation, reimbursement, patient experience and sustainable clinic strategy.
Sources: